Anupam Rasayan Recommends Final Dividend of ₹1.5/Share, Approves Financials & Acquisition
Anupam Rasayan's Board approved FY26 financial results and recommended a final dividend of ₹1.5 per share. The company will acquire up to 74.20% of Bliss GVS Pharma and raise ₹160 crore via NCDs. Mr. Vishal Thakkar resigned as Deputy CFO.
The announcement includes a dividend recommendation, approval of financial results, a significant acquisition, and a substantial debt fundraising plan, all of which can have a material impact on the company's financial position and strategic direction.
The company announced a recommended final dividend, approved financial results with an unmodified audit opinion, and approved strategic initiatives like acquisition and debt fundraising, which are generally positive indicators.
Anupam Rasayan India Limited announced the outcome of its Board Meeting held on May 23, 2026. The Board has approved the audited standalone and consolidated financial results for the quarter and financial year ended March 31, 2026. The company's statutory auditor, M/s. Natvarlal Vepari & Co., has issued an unmodified audit opinion on these results.
Furthermore, the Board has recommended a final dividend of ₹1.5 per equity share (15% of face value of ₹10) for the financial year 2025-26, subject to approval at the upcoming 23rd Annual General Meeting. The company also re-appointed M/s. KB. Daliya & Associates as Internal Auditors and M/s. Bhanwarlal Gurjar & Co. as Cost Auditors for the financial year 2026-27.
In significant strategic moves, the company approved the acquisition of up to 74.20% equity shares and control of Bliss GVS Pharma Limited. Additionally, Anupam Rasayan will raise funds by issuing 16,000 Secured, Rated, Unlisted, Redeemable, Non-Convertible Debentures aggregating up to ₹160 crore on a private placement basis.
The Board also accepted the resignation of Mr. Vishal Thakkar from the post of Deputy Chief Financial Officer and Key Managerial Personnel. The Board meeting commenced at 12:45 p.m. and concluded at 04:55 p.m. IST.
What to do with a filing like this
Anupam Rasayan India Limited filed this with the NSE as a statutory disclosure, categorised under dividend. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Anupam Rasayan India Limited. Read the original for the full detail.